Japan Antibody Drug Conjugates Market Size & Outlook
Japan antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Japan antibody drug conjugates market highlights
- The Japan antibody drug conjugates market generated a revenue of USD 474.4 million in 2021 and is expected to reach USD 1,861.0 million by 2030.
- The Japan market is expected to grow at a CAGR of 16.4% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Other Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 474.4 million |
| Market revenue in 2030 | USD 1,861.0 million |
| Growth rate | 16.4% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Other Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Other Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Japan accounted for 8.2% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 863.8 million by 2030.
Blood cancer was the largest segment with a revenue share of 44.65% in 2021. Horizon Databook has segmented the Japan antibody drug conjugates market based on blood cancer, breast cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
ADC drugs such as Kadcyla were approved by the Japanese Ministry of Health, Labour and Welfare in 2013. More recently, in August 2020, the drug was approved to be used as an adjuvant therapy of HER2-positive early breast cancer. In September 2020, Enhertu was approved for the treatment of gastric cancer in Japan.
Moreover, increasing number of ADC clinical trials are being conducted in the country. For instance, Japanese company Daiichi Sankyo is investing heavily in ADC development. Currently, it has three ADC products in clinical pipeline at multiple phases.
The approval of products currently in clinical trials, label expansion, and growing adoption of currently approved ADC drugs are factors expected to drive the market. Japan has been a favorable market for ADC manufacturers.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan antibody drug conjugates market size, by application, 2018-2030 (US$M)
Japan Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
